| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112–2699
This minireview is an update of a 1997 review on erythropoietin (EPO) in this journal (1). EPO is a 30,400-dalton glycoprotein that regulates red cell production. In the human, EPO is produced by peritubular cells in the kidneys of the adult and in hepatocytes in the fetus. Small amounts of extra-renal EPO are produced by the liver in adult human subjects. EPO binds to an erythroid progenitor cell surface receptor that includes a p66 chain, and, when activated, the p66 protein becomes dimerized. EPO receptor activation induces a JAK2 tyrosine kinase, which leads to tyrosine phosphorylation of the EPO receptor and several proteins. EPO receptor binding leads to intracellular activation of the Ras/mitogen-activated kinase pathway, which is involved with cell proliferation, phosphatidylinositol 3-kinase, and STATS 1, 3, 5A, and 5B transcriptional factors. EPO acts primarily to rescue erythroid cells from apoptosis (programmed cell death) to increase their survival. EPO acts synergistically with several growth factors (SCF, GM-CSF, 1L-3, and IGF-1) to cause maturation and proliferation of erythroid progenitor cells (primarily colony-forming unit-E). Oxygen-dependent regulation of EPO gene expression is postulated to be controlled by a hypoxia-inducible transcription factor (HIF-1
). Hypoxia-inducible EPO production is controlled by a 50-bp hypoxia-inducible enhancer that is approximately 120 bp 3' to the polyadenylation site. Hypoxia signal transduction pathways involve kinases A and C, phospholipase A2, and transcription factors ATF-1 and CREB-1. A model has been proposed for adenosine activation of EPO production that involves protein kinases A and C and the phospholipase A2 pathway. Other effects of EPO include a hematocrit-independent, vasoconstriction-dependent hypertension, increased endothelin production, upregulation of tissue renin, change in vascular tissue prostaglandins production, stimulation of angiogenesis, and stimulation of endothelial and vascular smooth muscle cell proliferation. Recombinant human EPO (rHuEPO) is currently being used to treat patients with anemias associated with chronic renal failure, AIDS patients with anemia due to treatment with zidovudine, nonmyeloid malignancies in patients treated with chemotherapeutic agents, perioperative surgical patients, and autologous blood donation. A novel erythropoiesis-stimulating factor (NESP, darbepoetin) has been synthesized and when compared with rHuEPO, NESP has a higher carbohydrate content (52% vs 40%), a longer plasma half-life, the amino acid sequence differs from that of native human EPO at five positions, and has been reported to maintain hemoglobin levels just as effectively in patients with chronic renal failure as rHuEPO at less frequent dosing. The use of rHuEPO and darbepoetin to enhance athletic performance is officially banned by most sports-governing bodies because the excessive erythrocytosis can lead to increased thrombogenicity and can cause deep vein, coronary, and cerebral thromboses.
Key Words: erythropoietin • darbepoetin • hypoxia • erythropoiesis • receptor • oxygen • hypoxia-inducible factor • adenosine • anemia • doping
This article has been cited by other articles:
|
|
 |
|
  C. Bartels, K. Spate, H. Krampe, and H. Ehrenreich Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 193 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Bouman-Thio, K. Franson, B. Miller, J. Getsy, A. Cohen, S. A. Bai, J. Yohrling, B. Frederick, S. Marciniak, Q. Jiao, et al. A Phase I, Single and Fractionated, Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects J. Clin. Pharmacol., October 1, 2008; 48(10): 1197 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brines, N. S. A. Patel, P. Villa, C. Brines, T. Mennini, M. De Paola, Z. Erbayraktar, S. Erbayraktar, B. Sepodes, C. Thiemermann, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin PNAS, August 5, 2008; 105(31): 10925 - 10930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. d'Uscio and Z. S. Katusic Erythropoietin Increases Endothelial Biosynthesis of Tetrahydrobiopterin by Activation of Protein Kinase B{alpha}/Akt1 Hypertension, July 1, 2008; 52(1): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Garcia-Ramirez, C. Hernandez, and R. Simo Expression of Erythropoietin and Its Receptor in the Human Retina: A comparative study of diabetic and nondiabetic subjects Diabetes Care, June 1, 2008; 31(6): 1189 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Mocini, P Muso, E Guendouz, L De Marco, L Mele, R Cini, P Sordini, A Alois, A Costantino, S Arima, et al. Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery Perfusion, May 1, 2008; 23(3): 187 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. P. Deudero, C. Caramelo, M. C. Castellanos, F. Neria, R. Fernandez-Sanchez, O. Calabia, S. Penate, and F. R. Gonzalez-Pacheco Induction of Hypoxia-inducible Factor 1{alpha} Gene Expression by Vascular Endothelial Growth Factor J. Biol. Chem., April 25, 2008; 283(17): 11435 - 11444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Artunc and T. Risler Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ditting, K. F. Hilgers, A. Stetter, P. Linz, C. Schonweiss, and R. Veelken Renal sympathetic nerves modulate erythropoietin plasma levels after transient hemorrhage in rats Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1099 - F1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kase, W. Saito, K. Ohgami, K. Yoshida, N. Furudate, A. Saito, M. Yokoi, M. Kase, and S. Ohno Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy Br. J. Ophthalmol., October 1, 2007; 91(10): 1376 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Paffett-Lugassy, N. Hsia, P. G. Fraenkel, B. Paw, I. Leshinsky, B. Barut, N. Bahary, J. Caro, R. Handin, and L. I. Zon Functional conservation of erythropoietin signaling in zebrafish Blood, October 1, 2007; 110(7): 2718 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Soliz, M. Gassmann, and V. Joseph Soluble erythropoietin receptor is present in the mouse brain and is required for the ventilatory acclimatization to hypoxia J. Physiol., August 15, 2007; 583(1): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lindenblatt, M. D. Menger, E. Klar, and B. Vollmar Darbepoetin-Alpha Does Not Promote Microvascular Thrombus Formation in Mice: Role of eNOS-Dependent Protection Through Platelet and Endothelial Cell Deactivation Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1191 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Kishore, J. Isaac, and C. Westenfelder Administration of poly-D-glutamic acid induces proliferation of erythropoietin-producing peritubular cells in rat kidney Am J Physiol Renal Physiol, February 1, 2007; 292(2): F749 - F761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bugarski, A. Krstic, S. Mojsilovic, M. Vlaski, M. Petakov, G. Jovcic, N. Stojanovic, and P. Milenkovic Signaling Pathways Implicated in Hematopoietic Progenitor Cell Proliferation and Differentiation Experimental Biology and Medicine, January 1, 2007; 232(1): 156 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Prunier, O. Pfister, L. Hadri, L. Liang, F. del Monte, R. Liao, and R. J. Hajjar Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H522 - H529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Woo, W. Krzyzanski, and W. J. Jusko Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1297 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Otero, H. B. Nguyen, D. T. Huang, D. F. Gaieski, M. Goyal, K. J. Gunnerson, S. Trzeciak, R. Sherwin, C. V. Holthaus, T. Osborn, et al. Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest, November 1, 2006; 130(5): 1579 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B Zimmermann, R. Biebinger, F. Rohner, A. Dib, C. Zeder, R. F Hurrell, and N. Chaouki Vitamin A supplementation in children with poor vitamin A and iron status increases erythropoietin and hemoglobin concentrations without changing total body iron. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hernandez, A. Fonollosa, M. Garcia-Ramirez, M. Higuera, R. Catalan, A. Miralles, J. Garcia-Arumi, and R. Simo Erythropoietin Is Expressed in the Human Retina and It Is Highly Elevated in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, September 1, 2006; 29(9): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Robinson, S Giraud, C Saudan, N Baume, L Avois, P Mangin, and M Saugy Erythropoietin and blood doping Br. J. Sports Med., July 1, 2006; 40(suppl_1): i30 - i34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
T. Miki, T. Miura, T. Yano, A. Takahashi, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, M. Nishihara, K. Naitoh, et al. Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E Cusick, J. M Tielsch, M. Ramsan, J. K Jape, S. Sazawal, R. E Black, and R. J Stoltzfus Short-term effects of vitamin A and antimalarial treatment on erythropoiesis in severely anemic Zanzibari preschool children Am. J. Clinical Nutrition, August 1, 2005; 82(2): 406 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aizawa, N. Nogawa, N. Kosaka, Y. Maeda, T. Watanabe, H. Miyazaki, and T. Kato Expression of Erythropoietin Receptor-Like Molecule in Xenopus laevis and Erythrocytopenia upon Administration of Its Recombinant Soluble Form J. Biochem., August 1, 2005; 138(2): 167 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, S. C. Postel, M. Tager, and S. M. Bode-Boger Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase J. Am. Soc. Nephrol., April 1, 2005; 16(4): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rui, Q. Feng, M. Lei, T. Peng, J. Zhang, M. Xu, E. Dale Abel, A. Xenocostas, and P. R. Kvietys Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1 Cardiovasc Res, February 15, 2005; 65(3): 719 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Beleslin-Cokic, V. P. Cokic, X. Yu, B. B. Weksler, A. N. Schechter, and C. T. Noguchi Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells Blood, October 1, 2004; 104(7): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Waskow, G. Terszowski, C. Costa, M. Gassmann, and H.-R. Rodewald Rescue of lethal c-KitW/W mice by erythropoietin Blood, September 15, 2004; 104(6): 1688 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Marti Erythropoietin and the hypoxic brain J. Exp. Biol., August 15, 2004; 207(18): 3233 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res, August 1, 2004; 63(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Gordeuk, A. I. Sergueeva, G. Y. Miasnikova, D. Okhotin, Y. Voloshin, P. L. Choyke, J. A. Butman, K. Jedlickova, J. T. Prchal, and L. A. Polyakova Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors Blood, May 15, 2004; 103(10): 3924 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grasso, A. Sfacteria, A. Cerami, and M. Brines Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go? Neuroscientist, April 1, 2004; 10(2): 93 - 98. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Rillema Hormone Regulation of Choline Uptake and Incorporation in Mouse Mammary Gland Explants Experimental Biology and Medicine, April 1, 2004; 229(4): 323 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Erbayraktar, G. Grasso, A. Sfacteria, Q.-w. Xie, T. Coleman, M. Kreilgaard, L. Torup, T. Sager, Z. Erbayraktar, N. Gokmen, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo PNAS, May 27, 2003; 100(11): 6741 - 6746. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
